|
評級理由主要包括：1）全年和Q4業績實現高速增長，低1.29元，院內院外共同發展；3）基藥預期與醫保解禁利好公司未來發展。 AI點評：康緣藥業近一個月獲得15份券商研報關注，買入11家，增持 |
光算蜘蛛池光算谷歌推广光算谷歌外链光算谷歌seo光算谷歌外鏈光算蜘蛛池光算谷歌外鏈光算谷歌seo代运营光算爬虫池光算谷歌seo光算谷歌营销https://brokerhivex.com/https://www.brokerhivex.com/cate-detail/38https://www.brokersearch.net/cate-detail/3https://www.brokerhivex.com/cate-detail/26https://www.brokerhivex.com/cate-detail/35https://www.brokerhivex.com/cate-detail/7https://www.brokerhivex.com/cate-detail/53https://www.brokerhivex.com/cate-detail/45https://www.brokerhivex.com/cate-detail/89https://www.brokerhivex.com/cate-detail/12https://www.brokerhivex.com/cate-detail/18https://www.brokerhivex.com/cate-detail/8https://www.brokerhivex.com/cate-detail/32https://www.brokerhivex.com/cate-detail/80https://www.brokerhivex.com/cate-detail/39https://www.brokerhivex.com/cate-detail/84https://www.brokerhivex.com/cate-detail/70https://www.brokerhivex.com/cate-detail/98https://www.brokersearch.net/cate-detail/8https://www.brokerhivex.com/cate-detail/52https://www.brokerhivex.com/cate-detail/87https://www.brokersearch.net/cate-detail/14https://www.brokerhivex.com/cate-detail/2https://www.brokerhivex.com/cate-detail/37https://www.brokerhivex.com/cate-detail/55https://www.brokerhivex.com/cate-detail/60https://www.brokerhivex.com/cate-detail/63https://www.brokerhivex.com/cate-detail/46https://www.brokersearch.net/cate-detail/9https://www.brokerhivex.com/cate-detail/93